.jpg "Ultragenyx (NASDAQ: RARE)")
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Ultragenyx (RARE). The company’s shares closed on Friday at $43, close to its 52-week low of $37.44.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.7% and a 42.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on Ultragenyx is a Moderate Buy with an average price target of $70.60.
See today’s analyst top recommended stocks >>
The company has a one-year high of $90.98 and a one-year low of $37.44. Currently, Ultragenyx has an average volume of 583.6K.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock. Most recently, in October 2018, Shalini Sharp, the CFO & EVP of RARE bought 12,000 shares for a total of $9,720.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
